Vienna Asset Management LLC Raises Position in Novo Nordisk A/S (NYSE:NVO)

Vienna Asset Management LLC lifted its stake in Novo Nordisk A/S (NYSE:NVO) by 83.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,022 shares of the company’s stock after buying an additional 2,283 shares during the period. Vienna Asset Management LLC’s holdings in Novo Nordisk A/S were worth $432,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Bank of America Corp DE boosted its position in shares of Novo Nordisk A/S by 8.1% in the fourth quarter. Bank of America Corp DE now owns 15,492,384 shares of the company’s stock worth $1,332,655,000 after buying an additional 1,165,955 shares during the period. GQG Partners LLC boosted its holdings in Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock valued at $1,117,790,000 after purchasing an additional 5,556,460 shares during the last quarter. Loomis Sayles & Co. L P boosted its holdings in Novo Nordisk A/S by 34.2% in the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock valued at $995,397,000 after purchasing an additional 2,947,771 shares during the last quarter. Folketrygdfondet boosted its holdings in Novo Nordisk A/S by 0.5% in the fourth quarter. Folketrygdfondet now owns 8,903,938 shares of the company’s stock valued at $765,917,000 after purchasing an additional 40,313 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Novo Nordisk A/S by 1.5% in the fourth quarter. Renaissance Technologies LLC now owns 8,312,996 shares of the company’s stock valued at $715,084,000 after purchasing an additional 123,681 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 2.7%

Shares of Novo Nordisk A/S stock opened at $64.35 on Monday. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The business’s 50 day simple moving average is $67.31 and its 200-day simple moving average is $84.19. The stock has a market capitalization of $288.75 billion, a price-to-earnings ratio of 19.56, a PEG ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analysts Set New Price Targets

NVO has been the subject of a number of analyst reports. Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, April 25th. Dbs Bank downgraded Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. BNP Paribas started coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an “underperform” rating on the stock. Finally, Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus target price of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.